MedTrace Logo

Human Umbilical Cord Mesenchymal Stem Cell in Cerebral Hemorrhage Sequela

NCT02283879 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-05-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cell(hUC-MSC) for cerebral hemorrhage sequela.

Conditions

  • Cerebral Hemorrhage

Interventions

BIOLOGICAL

Human umbilical cord mesenchymal stem cells

A single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.

Sponsors & Collaborators

  • Fifth Affiliated Hospital of Guangzhou Medical University

    collaborator OTHER

  • Shenzhen Hornetcorn Bio-technology Company, LTD

    lead INDUSTRY

Principal Investigators

  • Ping J Chen, Professor · Fifth Affiliated Hospital of Guangzhou Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2016-12-31
Completion
2017-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02283879 on ClinicalTrials.gov